FDA Slaps Clinical Hold on Zafgen’s Lead Product Over Safety Concerns

Shares of Boston-based Zafgen plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration (FDA) has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety concerns.